402
Participants
Start Date
October 31, 2005
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2009
Lantus
Patients in Group 1 will administer 80% of their usual insulin glargine dose.
Insulin
Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
Lantus
Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
William Beaumont Hospital, Royal Oak
William Beaumont Hospital, Troy
Collaborators (1)
Sanofi
INDUSTRY
Tamra Dukatz
OTHER